Breaking the Shield of Therapeutic Resistance: Baylor Researchers Develop Experimental Drug CS18 to Overcome Treatment-Refractory Tumors
Executive Overview In the ongoing war against oncology’s most formidable adversaries, therapeutic resistance remains the ultimate stronghold. Patients frequently experience initial clinical responses to state-of-the-art chemotherapies and targeted agents, only…